SNY 241220 47.50P (SNY241220P47500) Stock Options, News & Quotes

US OptionsDetailed Quotes

SNY241220P47500

Watchlist

0.95
+0.10+11.76%

15min DelayClose Nov 19 16:00 ET

0.95High0.90Low

Intraday

5D
Daily

News

FDA Accepts SNY and REGN's Dupixent Re-Submitted SBLA for Urticaria
Zacks Nov 18 14:30 ET
Sanofi's Sarclisa Nears EU Approval for Myeloma
TipRanksNov 18 12:49 ET
Express News | Us CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada
BenzingaNov 18 11:34 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
PFE, Moderna Shares Fall As Trump's RFK Pick Weighs on Vaccine Makers
WSJNov 15 10:09 ET
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
BenzingaNov 15 08:44 ET

Comments

Meltyy

Sep 25 06:31

See FDA PDUFA update 👀 👇

🚨 This Week’s PDUFAs:
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...

Meltyy

Sep 10 04:37

📅 FDA PDUFA & AdCom Update…

📣 ITRM AdCom 9/9 meeting ongoing 🚗
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...

Trytosaveabit

Sep 9 15:10

Update

$Vir Biotechnology (VIR.US)$ $Sanofi (SNY.US)$ Reuters· 4 mins ago
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

whqqq

Sep 2 21:13

Sanofi (SNYNF) Gets a Hold from J.P. Morgan

$JPMorgan (JPM.US)$ analyst Richard Vosser has maintained a Hold rating on Sanofi with a price target of €100.00.
The stock recently closed at $113.65, with a consensus price target of $117.74, indicating a potential upside of 3.60%.
Sanofi's market cap stands at $141.1 billion, with a P/E ratio of 30.47.
$Sanofi (SNY.US)$

Meltyy

Aug 27 01:16

FDA PDUFA Update:

🚀 Buckle up for upcoming PDUFAs in September! 👇
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...